STUDIES ON TRANSACTIVATION BY HUMAN T CELL LEUKEMIA VIRUS NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


STUDIES ON TRANSACTIVATION BY HUMAN T CELL LEUKEMIA VIRUS

Diss Abstr Int [B]; 50(9):3846 1990. Unique Identifier : AIDSLINE ICDB/90665700
Kitado H; Univ. of California, Irvine


Abstract: We have inserted sequences from the human T-cell leukemia viruses (HTLVs) that are responsive to tax, into the long terminal repeats (LTRs) of Moloney murine leukemia virus (M-MuLV). The inserted HTLV sequences conferred tax-response to the Moloney promoter in transient expression assays whether or not the Moloney enhancers were also present in the LTR. Infectious recombinant M-MuLVs containing chimeric LTRs were also generated, and found to be responsive to tax in infectivity. These recombinant M-MuLVs, which contained tax-responsive sequences from the HTLV-II LTR in addition to, or in substitution for the Moloney enhancers, were infected into both NIH-3T3 cell line and a tax-producing NIH-3T3 cell line (15S-5a), and the chromatin structures of the proviruses were analyzed by DNase I hypersensitive (HS) site mapping technique. The results indicated that tax does not change the chromatin structure. Furthermore, presence of HS sites associated with the HTLV 21 bp repeats suggested binding of cellular factors to these sequences. When cellular factors that specifically bind to the HTLV 21 bp element were examined by UV cross-linking technique, some novel factors were discovered. These increased their affinity for the 21 bp element with increasing concentration of the 21 bp element. Binding activities of several factors were found to be dependent upon the growth state of cells, and to be altered by cAMP levels. The chimeric M-MuLV that contained the tax-responsive sequences of HTLV-II within the wild type Moloney LTRs was also injected into neonatal mice, and the tumors induced were analyzed. 11 out of 12 animals had T-cell leukemias, with 6 of them showing a possibly novel type of T-cell leukemia. The results suggest that the inserted HTLV sequences may have altered the type of disease normally induced by the wild type M-MuLV. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD90-05436)
Keywords: Animal Cell Line Enhancer Elements (Genetics) Gene Expression Regulation, Viral Human HTLV-BLV Viruses/*GENETICS Leukemia, Experimental/GENETICS Leukemia, T-Cell/GENETICS Mice Moloney Leukemia Virus/GENETICS Recombination, Genetic Repetitive Sequences, Nucleic Acid *Trans-Activation (Genetics) Trans-Activators/GENETICS THESISKWDanimalcelllineenhancerelements(genetics)geneexpressionregulation,viralhumanhtlv-blvviruses/KWDgeneticsleukemia,experimental/geneticsleukemia,t-cell/geneticsmicemoloneyleukemiavirus/geneticsrecombination,geneticrepetitivesequences,nucleicacidKWDtrans-activation(genetics)trans-activators/geneticsthesis
900930
M9094777

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .